New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

Trial Title: New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

NCT ID: NCT05728931

Condition: Paraneoplastic Neurological Syndrome
Autoimmune Encephalitis

Conditions: Official terms:
Paraneoplastic Syndromes
Encephalitis
Autoimmune Diseases of the Nervous System
Syndrome

Conditions: Keywords:
Paraneoplastic Neurological Syndrome
Autoimmune Encephalitis

Study type: Observational

Overall status: Active, not recruiting

Study design:

Time perspective: Retrospective

Intervention:

Intervention type: Biological
Intervention name: Test of biological samples
Description: Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title

Summary: Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.

Criteria for eligibility:

Study pop:
Patient without antibodies known with neurological disorder and include in biobank of "centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".

Sampling method: Non-Probability Sample
Criteria:
- Inclusion Criteria * : - patient with neurological disorder - patient without antibody - Exclusion Criteria * : - patient with characterized antibody - patient without neurological disorder

Gender: All

Minimum age: N/A

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes

Address:
City: Lyon
Zip: 69677
Country: France

Start date: January 15, 2022

Completion date: January 15, 2032

Lead sponsor:
Agency: Hospices Civils de Lyon
Agency class: Other

Source: Hospices Civils de Lyon

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05728931